OPTIMER PHARMACEUTICALS INC 4

Accession 0001142576-13-000024

CIK 0001142576operating

Filed

Oct 27, 8:00 PM ET

Accepted

Oct 28, 5:42 PM ET

Size

24.6 KB

Accession

0001142576-13-000024

Form 4

Period: 2013-10-24

SVP, Chief Medical Officer

Transactions

Disposition to Issuer
Common stock
2013-10-24$10.75/sh−2,333$25,080→ 0 total
Disposition to Issuer
Stock option (right to buy)
2013-10-24$11.70/sh−11,610$135,837→ 0 total
Exercise: $1.08Exp: 2015-12-02→ Common stock (11,610 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-10-24$2.06/sh−60,000$123,600→ 0 total
Exercise: $10.72Exp: 2023-02-26→ Common stock (60,000 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-10-24$11.70/sh−1,298$15,187→ 0 total
Exercise: $1.08Exp: 2015-12-02→ Common stock (1,298 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-10-24$6.19/sh−100,000$619,000→ 0 total
Exercise: $6.59Exp: 2018-03-12→ Common stock (100,000 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-10-24$3.75/sh−20,000$75,000→ 0 total
Exercise: $9.03Exp: 2020-09-15→ Common stock (20,000 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-10-24$1.37/sh−40,000$54,800→ 0 total
Exercise: $11.41Exp: 2021-01-26→ Common stock (40,000 underlying)
Disposition to Issuer
Common stock
2013-10-24$10.75/sh−39,886$428,775→ 2,333 total
Disposition to Issuer
Stock option (right to buy)
2013-10-24$5.88/sh−7,500$44,100→ 0 total
Exercise: $6.90Exp: 2018-01-04→ Common stock (7,500 underlying)
Disposition to Issuer
Stock option (right to buy)
2013-10-24$0.93/sh−12,000$11,160→ 0 total
Exercise: $11.85Exp: 2020-01-08→ Common stock (12,000 underlying)

Footnotes (4)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of July 30, 2013 (the "Merger Agreement"), among Optimer Pharmaceuticals, Inc. ("Optimer"), Cubist Pharmaceuticals, Inc. ("Cubist"), and PDRS Corporation, shares were converted into the right to receive per share consideration of: (i) $10.75 cash and (ii) one contingent value right issued by Cubist in accordance with the Contingent Value Rights Agreement, dated as of October 24, 2013, between Cubist and American Stock Transfer & Trust Company, LLC (together, the "Per Share Merger Consideration").
[F2]Pursuant to the terms of the Merger Agreement, each award was fully vested and converted into the right to receive the Per Share Merger Consideration with respect to each share of Optimer common stock subject to the award.
[F3]Pursuant to the terms of the Merger Agreement, each option was converted into the right to receive a cash payment equal to the excess, if any, of $12.78 (the last reported sale price of a share of Optimer common stock on The NASDAQ Global Select Market on October 23, 2013) over such option's per share exercise price.
[F4]Pursuant to the terms of the Merger Agreement, each option was fully vested and converted into the right to receive a cash payment equal to the excess, if any, of $12.78 (the last reported sale price of a share of Optimer common stock on The NASDAQ Global Select Market on October 23, 2013) over such option's per share exercise price.

Documents

1 file

OPTIMER PHARMACEUTICALS INC

CIK 0001142576

Entity typeoperating